Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Bacterial Populations Rapidly Evolve a Time-linked Tolerance to Antibiotics

By BiotechDaily International staff writers
Posted on 14 Jul 2014
A team of molecular microbiologists has found that some types of bacteria develop tolerance towards antibiotic treatment by "learning" how to time the length of exposure to the drug and evolving an extended period of dormancy that protects the organisms from the effects of the antibiotic.

Investigators at the Hebrew University of Jerusalem (Israel) followed the evolution of bacterial populations under intermittent exposure to the high concentrations of antibiotics used in the clinic and characterized the evolved strains in terms of both resistance (growth of microorganisms in the constant presence of an antibiotic, provided that the concentration of the antibiotic is not too high) and tolerance (survival of microorganisms during antibiotic treatment, even at high antibiotic concentrations, as long as the duration of the treatment is limited).

Initially bacterial populations were treated with antibiotics for three hours each day. Exposure times were later increased to five and eight hours per day.

By monitoring the phenotypic changes at the population and single-cell levels, the investigators found that after only 10 days the first adaptive change to antibiotic stress became apparent. This was the development of tolerance towards the antibiotic through a major adjustment in the single-cell lag-time distribution, without a change in resistance. They also found that the lag time of bacteria before regrowth was optimized to match the duration of the antibiotic-exposure interval. All bacterial strains adapted by specific genetic mutations, which became fixed in the evolved populations.

The investigators also reported that whole genome sequencing of the evolved strains and restoration of the wild-type alleles allowed the identification of target genes involved in this antibiotic-driven phenotype, which they called "tolerance by lag" (tbl).

The results of this study, which was published in the June 25, 2014, online edition of the journal Nature, demonstrated that bacteria can evolve within days. The investigators expect that better understanding of lag-time evolution as a key determinant of the survival of bacterial populations under high antibiotic concentrations will lead to new approaches to preventing the evolution of antibiotic resistance.

Related Links:

Hebrew University of Jerusalem



comments powered by Disqus

Channels

Drug Discovery

view channel

Ibuprofen May Restore Immune Function in Older Individuals

New research suggests that macrophages from the lungs of old mice respond differently to infections than those of young mice, and ibuprofen given to the mice reversed these changes. New research using lab mice suggests that the solution to more youthful immune function might already be a common over-the-counter pain reliever.... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel
Image: Leica Microsystems launches the inverted research microscope platform Leica DMi8 (Photo courtesy of Leica Microsystems).

New Inverted Microscope Designed to Readily Adapt to Changing Research Demands

A new inverted microscope for biotech and other life science laboratories was designed to readily accommodate modifications and upgrades to allow it to keep current with changing research demands and interests.... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.